Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press35510.17650/1726-9776-2010-6-4-47-53PROSTATE CANCERРАК ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫPROGNOSTIC FACTORS IN PROSTATE CANCERФАКТОРЫ ПРОГНОЗА ПРИ РАКЕ ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫGorbanN. A.ГорбаньН. А.
Russian Federation
perovanina@mail.ruKaryakinA. O.КарякинА. О.
Russian Federation
perovanina@mail.ruMedical Radiology Research Center, Russian Academy of Medical Sciences, ObninskГУ МРНЦ РАМН, Обнинск301220106447530708201407082014https://oncourology.abvpress.ru/oncur/article/view/355

Prostate cancer is most common and its heterogenicity is presently apparent. There is a continuous search for the factors allowing the prediction of the poor course and biological difference of tumors. The College of American Pathologists classifies the currently known prognostic factors into 3 categories: 1) the factors whose prognostic importance and successful use have been proven in practice; 2) those that have been widely studied biologically and clinically, but the significance of which needs to be proven in extensive statistical studies; 3) all other factors that have been inadequately studied to demonstrate their prognostic value. Category 1 prognostic factors, such as prostate-specific antigen levels, TNM stage, Gleason grading, and the status of surgical margins, enjoy wide application. Category 2 factors are not used IN clinical practice so extensively. The value of some Category 3 factors (the biomarkers p53, Ki-67, Bcl-2, receptors of androgens) is indubitably and they claim to be widely applied in clinical practice with time. The clinical significance of molecular biological markers calls for further investigation.

Рак предстательной железы широко распространен, и в настоящее время очевидной является гетерогенность этого заболевания. Постоянно идут поиски факторов, позволяющих предсказать неблагоприятное течение и биологическое различие опухолей. Коллегия американских патологов (College of American Pathologists) классифицировала известные в настоящее время прогностические факторы на 3 категории: I категория - факторы, прогностическая важность и успешное применение которых в практике доказаны; II - факторы, которые широко изучены биологически и клинически, но значимость которых требуется доказать в широких статистических исследованиях; III - все другие факторы, которые недостаточно изучены, чтобы продемонстрировать их прогностическую ценность. Широкое клиническое применение имеют прогностические факторы I категории, такие как уровень простатспецифического антигена, стадия TNM, градация Глисона и состояние хирургических краев. Факторы II категории не так широко используются в клинической практике. Ценность некоторых факторов III категории (биомаркеры р53, Ki-67, Bcl-2, рецепторы андрогенов) несомненна, и со временем они претендуют на широкое применение в клинической практике. Значение молекулярно-биологических маркеров для клиники требует дальнейшего изучения.

prostate cancertumor progressionmolecular biological markersрак предстательной железыопухолевая прогрессиямолекулярно-биологические маркеры1. Buhmeida A., Pyrhönen S., Laato M., Collan Y. Prognostic factors in prostate cancer.Diagn Pathol 2006;3:1–4.Buhmeida A., Pyrhönen S., Laato M., Collan Y. Prognostic factors in prostate cancer.Diagn Pathol 2006;3:1–4.2. World Health Organization Classification of Tumours. Pathology & genetics: tumours of the urinary system and male genital organs. Lyon, France: IARC Press, 2004; p. 179–184.World Health Organization Classification of Tumours. Pathology & genetics: tumours of the urinary system and male genital organs. Lyon, France: IARC Press, 2004; p. 179–184.3. Bostwick D.G., Grignon D.J., Hammond M.E. et al. Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000;124(7):995–1000.Bostwick D.G., Grignon D.J., Hammond M.E. et al. Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000;124(7):995–1000.4. Stamey T.A., Yang N., Hay A.R. et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317(15):909–16.Stamey T.A., Yang N., Hay A.R. et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317(15):909–16.5. Catalona W.J., Richie J.P., Ahmann F.R. et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 1994;151(5):1283–90.Catalona W.J., Richie J.P., Ahmann F.R. et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 1994;151(5):1283–90.6. Thompson I.M., Pauler D.K., Goodman P.J. et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 2004;350(22):2239–46.Thompson I.M., Pauler D.K., Goodman P.J. et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 2004;350(22):2239–46.7. Hessels D., Klein Gunnewiek J.M.T., van Oort I. et al. DD3 (PSA3) – based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003;44:8–5; discussion 15–6.Hessels D., Klein Gunnewiek J.M.T., van Oort I. et al. DD3 (PSA3) – based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003;44:8–5; discussion 15–6.8. Kattan M.W., Stapleton A.M.F., Wheeler T.M., Scardino P.T. Evaluation of a nomogram used to predict the pathologic stage of clinically localized prostate carcinoma. Cancer 1997;79:528–37.Kattan M.W., Stapleton A.M.F., Wheeler T.M., Scardino P.T. Evaluation of a nomogram used to predict the pathologic stage of clinically localized prostate carcinoma. Cancer 1997;79:528–37.9. Kattan M.W., Eastham J.A., Stapleton A.M. et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998;90:766–71.Kattan M.W., Eastham J.A., Stapleton A.M. et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998;90:766–71.10. Partin A.W., Kattan M.W., Subong E.N.P. et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathologic stage of localized prostate cancer: a multi-institutional update. JAMA 1997;277:1445–51.Partin A.W., Kattan M.W., Subong E.N.P. et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathologic stage of localized prostate cancer: a multi-institutional update. JAMA 1997;277:1445–51.11. Gleason D.F. Classification of prostatic carcinomas. Cancer Chemother Rep 1966;50:125–8.Gleason D.F. Classification of prostatic carcinomas. Cancer Chemother Rep 1966;50:125–8.12. Sebo T.J., Ceville J.C., Riele D.L. et al. Perineural invasion and MIB-1 positivity in addition to Gleason score are significant preoperative predictors of progression after radical retropubic prostatectomy for prostate cancer. AJSP 2002:26(4):431–39.Sebo T.J., Ceville J.C., Riele D.L. et al. Perineural invasion and MIB-1 positivity in addition to Gleason score are significant preoperative predictors of progression after radical retropubic prostatectomy for prostate cancer. AJSP 2002:26(4):431–39.13. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostate Carcinoma. Am J Surg Pathol 005;29:1228–42.The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostate Carcinoma. Am J Surg Pathol 005;29:1228–42.14. Petersen R.O., Sesterhenn I.A., Davis C.J. Urologic Pathology. Philadelphia: Lippincott Williams &Wilkins, 2008.Petersen R.O., Sesterhenn I.A., Davis C.J. Urologic Pathology. Philadelphia: Lippincott Williams &Wilkins, 2008.15. Yossepowich O., Bjartell A., Easthem J.A. et al. Positive surgical margins in radical prostatectomy: outlining the problem and its long-term consequences. Eur Urol 2009;55:87–99.Yossepowich O., Bjartell A., Easthem J.A. et al. Positive surgical margins in radical prostatectomy: outlining the problem and its long-term consequences. Eur Urol 2009;55:87–99.16. Epstain J.I., Amin M., Boccon-Gibot L. et al. Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens. Scand J Urol Nephrol Suppl 2005;216:34–63.Epstain J.I., Amin M., Boccon-Gibot L. et al. Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens. Scand J Urol Nephrol Suppl 2005;216:34–63.17. Sofer M., Hamilton-Nelson K.L., Civantos F., Soloway M.S. Positive surgical margins after radical retropubic prostatectomy: the influence of site and number on progression. J Urol 2002;167:2453–6.Sofer M., Hamilton-Nelson K.L., Civantos F., Soloway M.S. Positive surgical margins after radical retropubic prostatectomy: the influence of site and number on progression. J Urol 2002;167:2453–6.18. Epstain J.I., Pizov G., Walsh P.C. Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer 1993;71:3582–93.Epstain J.I., Pizov G., Walsh P.C. Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer 1993;71:3582–93.19. Pettus J.A., Weight C.J., Thompson C.J. et al. Biochemical failure in man following radical retropubic prostatectomy: impact of surgical margin status and location. J Urol 2004;172:129–32.Pettus J.A., Weight C.J., Thompson C.J. et al. Biochemical failure in man following radical retropubic prostatectomy: impact of surgical margin status and location. J Urol 2004;172:129–32.20. Bloom K.D., Richie J.P., Schultz D. et al. Invasion of seminal vesicles by adenocarcinoma of the prostate: PSA outcome determined by preoperative and postoperative factors. Urology 2004;64(2):333–6.Bloom K.D., Richie J.P., Schultz D. et al. Invasion of seminal vesicles by adenocarcinoma of the prostate: PSA outcome determined by preoperative and postoperative factors. Urology 2004;64(2):333–6.21. Debras B., Guillonneau B., Bougaran J. et al. Prognostic significant of eminal vesicles invasion on the radical prostatectomy specimen. Rationale for seminal vesicles biopsies. Eur Urol 1998;33:271–7.Debras B., Guillonneau B., Bougaran J. et al. Prognostic significant of eminal vesicles invasion on the radical prostatectomy specimen. Rationale for seminal vesicles biopsies. Eur Urol 1998;33:271–7.22. McNeal J.E., Villers A.A., Redwine E.A. et al. Capsular penetration in prostate cancer. Significance for natural history and treatment. Am J Surg Pathol 1990;14:240–7.McNeal J.E., Villers A.A., Redwine E.A. et al. Capsular penetration in prostate cancer. Significance for natural history and treatment. Am J Surg Pathol 1990;14:240–7.23. Epstain J.I., Carmichael M., Partin A.W., Walsh P.C. Is tumour volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage III B adenocarcinomas of the prostate with 5 years of followup. J Urol 1993;149:1478–81.Epstain J.I., Carmichael M., Partin A.W., Walsh P.C. Is tumour volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage III B adenocarcinomas of the prostate with 5 years of followup. J Urol 1993;149:1478–81.24. Bostwick D.G., Graham S.D., Napalcov P. et al. Staging of early prostate cancer: a proposed tumour volume-based prognostic index. Urology 1993;41:403–11.Bostwick D.G., Graham S.D., Napalcov P. et al. Staging of early prostate cancer: a proposed tumour volume-based prognostic index. Urology 1993;41:403–11.25. Quinn D.I., Henshall S.M., Sutherland R.L. Molecular markers of prostate cancer outcome. Eur J Cancer 2005;41:858–87.Quinn D.I., Henshall S.M., Sutherland R.L. Molecular markers of prostate cancer outcome. Eur J Cancer 2005;41:858–87.26. Bettencourt M.C., Bauer J.J., Sesterhenn I.A. et al. Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy. J Urol 1996;156:1064–8.Bettencourt M.C., Bauer J.J., Sesterhenn I.A. et al. Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy. J Urol 1996;156:1064–8.27. Bubendorf L., Sauter G., Moch H. et al. Ki-67 labelling index: an independent predictor of progression in prostate cancer treated by radical prostatectomy. J Path 1996;178:437–41.Bubendorf L., Sauter G., Moch H. et al. Ki-67 labelling index: an independent predictor of progression in prostate cancer treated by radical prostatectomy. J Path 1996;178:437–41.28. Aaltomaa S., Lipponen P., Vesalainen S. et al. Value of Ki-67 immunolabelling as a prognostic factor in prostate cancer. Eur Urol 1997;3:2410–5.Aaltomaa S., Lipponen P., Vesalainen S. et al. Value of Ki-67 immunolabelling as a prognostic factor in prostate cancer. Eur Urol 1997;3:2410–5.29. Thomas D.J., Robinson M., King P. et al. p53 expression and clinical outcome in prostate cancer. Br J Urol 1993;72:778–81.Thomas D.J., Robinson M., King P. et al. p53 expression and clinical outcome in prostate cancer. Br J Urol 1993;72:778–81.30. Shurbaji M.S., Kalbfleisch J.H., Thormond T.S. Immunohistochemical detection of p53 protein as prognostic indicator in prostate cancer. Hum Pathol 995;26:106–9.Shurbaji M.S., Kalbfleisch J.H., Thormond T.S. Immunohistochemical detection of p53 protein as prognostic indicator in prostate cancer. Hum Pathol 995;26:106–9.31. Papadopoulos I., Rudolph P., Wirth B., Weichert J.K. P53 expression, proliferation marker Ki-67. DNA content and serum PSA: possible biopotential markers in human prostatic cancer. Urology 1996;48:261–8.Papadopoulos I., Rudolph P., Wirth B., Weichert J.K. P53 expression, proliferation marker Ki-67. DNA content and serum PSA: possible biopotential markers in human prostatic cancer. Urology 1996;48:261–8.32. Revelos K., Petraki C., Gregorakis A. et al. Immunohistochemical expression of Bcl-2 is an independent predictor of time-to-biochemical failure in patients with clinically localized prostate cancer following radical prostatectomy. Anticancer Res 2005;25(4):3123–33.Revelos K., Petraki C., Gregorakis A. et al. Immunohistochemical expression of Bcl-2 is an independent predictor of time-to-biochemical failure in patients with clinically localized prostate cancer following radical prostatectomy. Anticancer Res 2005;25(4):3123–33.33. Fleishman A., Schlomm T., Huland H. et al. Tissue microarray of prostate cancer: successful survival stratification based on the heterogeneously distributed tumor markers Bcl-2 and Ki-67. Virchows Arch 2009;455:229.Fleishman A., Schlomm T., Huland H. et al. Tissue microarray of prostate cancer: successful survival stratification based on the heterogeneously distributed tumor markers Bcl-2 and Ki-67. Virchows Arch 2009;455:229.34. Moul J.W., Bettencourt M.C., Sesterhenn I.A. et al. Protein expression of p53, Bcl-2, and Ki-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer. Surgery 1996;120:159–66.Moul J.W., Bettencourt M.C., Sesterhenn I.A. et al. Protein expression of p53, Bcl-2, and Ki-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer. Surgery 1996;120:159–66.35. Theodorescu D., Broder S.R., Boyd J.C. et al. p53, Bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate. J Urol 1997;158:131–7.Theodorescu D., Broder S.R., Boyd J.C. et al. p53, Bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate. J Urol 1997;158:131–7.36. Grignon D.J., Caplan R., Sarkar F.H. et al. p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610. J Natl Cancer Inst 1997;89:158–65.Grignon D.J., Caplan R., Sarkar F.H. et al. p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610. J Natl Cancer Inst 1997;89:158–65.37. Stattin P., Westin P., Damber J.E. et al. Short-term cellular effects induced by castration therapy in relation to clinical outcome in prostate cancer. Br J Cancer 1998;77:670–5.Stattin P., Westin P., Damber J.E. et al. Short-term cellular effects induced by castration therapy in relation to clinical outcome in prostate cancer. Br J Cancer 1998;77:670–5.38. Che M.D., De Silvio M., Pollac A. et al. Prognostic value of abnormal p53 expression in locally advanced prostate cancer treated with androgen deprivation and radiotherapy: a study based on RTOG 9202. J Radiat Oncol 2007;69:1117–23.Che M.D., De Silvio M., Pollac A. et al. Prognostic value of abnormal p53 expression in locally advanced prostate cancer treated with androgen deprivation and radiotherapy: a study based on RTOG 9202. J Radiat Oncol 2007;69:1117–23.39. Scherr D.S., Vaughan E.D., Wei J. et al. Bcl-2 and p53 expression in clinically localized prostate cancer predicts response to external beam radiotherapy. J Urol 1999;162:12–6.Scherr D.S., Vaughan E.D., Wei J. et al. Bcl-2 and p53 expression in clinically localized prostate cancer predicts response to external beam radiotherapy. J Urol 1999;162:12–6.40. Wilson C.M., Griffin J.E., Wilson J.D. et al. Immunoreactive androgen receptor expression in subgects with androgen resistence. J Clin Endocrinol Metab 1992;75:1474–8.Wilson C.M., Griffin J.E., Wilson J.D. et al. Immunoreactive androgen receptor expression in subgects with androgen resistence. J Clin Endocrinol Metab 1992;75:1474–8.41. Sweat S.D., Pacelli A., Bergstralh E.G. Androgen receptor expression in prostate intraepithelial neoplasia and cancer. J Urol 1999;161:1229–32.Sweat S.D., Pacelli A., Bergstralh E.G. Androgen receptor expression in prostate intraepithelial neoplasia and cancer. J Urol 1999;161:1229–32.